Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Vertex Pharmaceuticals Incorporated (VRTX) Surges On Study Results

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares have popped almost 19% in the pre-market after the company released positive results from two studies. Specifically, two phase 3 studies concerning the Tezacaftor/Ivacaftor combination met the primary endpoints in terms of statistically significant improvements in the lung function metric in people with cystic fibrosis ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator gene. In addition to solid efficacy, the combination was also well tolerated.

Dr. Jeffrey Chodakewitz said:

“The tezacaftor/ivacaftor combination treatment demonstrated clinically meaningful benefits, with a favorable safety profile, across multiple patient groups. This combination treatment may provide a promising new option for treating the underlying cause of CF in the future and brings us increasingly closer to our goal of developing new medicines for all people with the disease.”

In addition, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) received the thumbs up from Citi today, with analyst Robyn Karnauskas hiking her price target to $124 from the previous $105. Karnauskas thinks the positive tezacaftor data removes an overhang from the company’s future development plans. Needless to say, the analyst has a ‘Buy’ recommendation on the stock.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

Of the 742 top institutions in our database, 31 were long $643.39 million of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and accounted for 3.50% of the float on December 31, versus 33 funds and $454.49 million respectively at the end of September. Samuel Isaly‘s Orbimed Advisors raised its stake by 34% to over 2.1 million shares while John Overdeck And David Siegel‘s Two Sigma Advisors hiked its holdings by 321% to almost 1.1 million shares in the fourth quarter.

The Bottom Line

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are surging on the back of positive study results. Meanwhile, Wall Street has become more positive.

Follow Vertex Pharmaceuticals Inc / Ma (NASDAQ:VRTX)
Trade (NASDAQ:VRTX) Now!

Disclosure:None

Wall Street Bull

Wall Street Bull